Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 4:24 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 96 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Lupron Clear all
Completed Phase 3 Interventional Results available

Study of Leuprolide Acetate Injectable Suspension in the Treatment of Central Precocious Puberty

NCT02452931
View directory record Official record
Conditions
Precocious Puberty, Central
Interventions
Leuprolide Acetate 45 mg
Drug
Lead sponsor
Tolmar Inc.
Industry
Eligibility
2 Years to 9 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
10
States / cities
San Diego, California • Hollywood, Florida • Jacksonville, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2020 · Synced Oct 24, 2026, 4:24 AM EDT
Not listed Phase 2Phase 3 Interventional Accepts healthy volunteers

Lupron Sex Offender Therapy

NCT00220350
View directory record Official record
Conditions
Pedophilia
Interventions
leuprolide acetate
Drug
Lead sponsor
Schober, Justine, M.D.
Individual
Eligibility
18 Years and older · Male only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2005
U.S. locations
1
States / cities
Erie, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 22, 2005 · Synced Oct 24, 2026, 4:24 AM EDT
Terminated Phase 4 Interventional

Study of a Progestin to Prevent Bleeding Associated With Initiation of Medical Menopause With GnRH Agonist

NCT01776203
View directory record Official record
Conditions
Dysfunctional Uterine Bleeding
Interventions
Medroxyprogesterone 17-Acetate
Drug
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 17, 2015 · Synced Oct 24, 2026, 4:24 AM EDT
Completed Phase 1 Interventional

Sunitinib Malate, Hormone Ablation and Radiation Therapy in Patients With Prostate Cancer

NCT00631527
View directory record Official record
Conditions
Prostate Cancer
Interventions
Leuprolide, Goserelin, Sunitinib Malate, Casodex, Radiation Therapy (RT)
Drug · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 29, 2015 · Synced Oct 24, 2026, 4:24 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Understanding Experimentally Induced Hot Flushes

NCT00455689
View directory record Official record
Conditions
Hot Flashes
Interventions
Leuprolide acetate
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 18, 2018 · Synced Oct 24, 2026, 4:24 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Effects on the Brain of Lupron Induced Hypogonadotropic Hypogonadism With and Without Testosterone Replacement

NCT00001412
View directory record Official record
Conditions
Hypogonadism
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
Male only
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1993 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 24, 2026, 4:24 AM EDT
Completed Phase 2 Interventional Results available

Bay98-7196, Dose Finding / POC Study

NCT02203331
View directory record Official record
Conditions
Endometriosis
Interventions
Placebo, Levonorgestrel, Anastrozole, Lupron / Leuprolide acetate
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Female only
Enrollment
319 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
25
States / cities
San Diego, California • San Francisco, California • Gainesville, Florida + 22 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2023 · Synced Oct 24, 2026, 4:24 AM EDT
Completed Phase 3 Interventional Results available

Randomized Study to Evaluate MACE in Patients With Prostate Cancer Treated With Relugolix or Leuprolide Acetate

NCT05605964
View directory record Official record
Conditions
Prostate Cancer
Interventions
Relugolix, Leuprolide Acetate
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
387 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
108
States / cities
Mobile, Alabama • Tucson, Arizona • Little Rock, Arkansas + 83 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 24, 2026, 4:24 AM EDT
Active, not recruiting Phase 2 Interventional

Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation

NCT01746849
View directory record Official record
Conditions
Leukemia, Multiple Myeloma, Myelodysplastic Syndrome, Non-Hodgkin's Lymphoma
Interventions
Palifermin, Lupron, peripheral blood stem cell transplantation, Total-Body Irradiation (TBI), Thiotepa, Cyclophosphamide, Degarelix
Biological · Procedure · Radiation + 1 more
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 60 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Oct 24, 2026, 4:24 AM EDT
Active, not recruiting Phase 2 Interventional

Testing the Anti-cancer Drug Darolutamide in Patients With Testosterone-Driven Salivary Gland Cancers

NCT05669664
View directory record Official record
Conditions
Locally Advanced Salivary Gland Carcinoma, Metastatic Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma, Unresectable Salivary Gland Carcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Darolutamide, Leuprolide Acetate, Magnetic Resonance Imaging
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
27
States / cities
Irvine, California • Los Angeles, California • Orange, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 24, 2026, 4:24 AM EDT
Not listed Phase 3 Interventional

Treatment of Endometriosis With Norethindrone Acetate ( NA) VS. Gonadotropin- Releasing Hormone (GnRH) Agonist (Lupron Depot 11.25 mg)

NCT00458458
View directory record Official record
Conditions
Endometriosis, Dysmenorrhea, Dyspareunia
Interventions
Norethindrone Acetate (NA), GnRH Agonist (Lupron Depot)
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
18 Years to 55 Years · Female only
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Oct 25, 2012 · Synced Oct 24, 2026, 4:24 AM EDT
Terminated Phase 3 Interventional

Efficacy and Safety Study of a New Leuprolide Acetate 17 mg Depot to Treat Prostate Cancer Patients

NCT00630799
View directory record Official record
Conditions
Prostate Cancer
Interventions
leuprolide acetate
Drug
Lead sponsor
GP-Pharm
Industry
Eligibility
18 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
8
States / cities
New Port Richey, Florida • Lawrenceville, New Jersey • Poughkeepsie, New York + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2010 · Synced Oct 24, 2026, 4:24 AM EDT
Completed Phase 2 Interventional Results available

Hormonal Ablation, Imatinib Mesylate and Docetaxel for Patients With Prostate Cancer

NCT00500110
View directory record Official record
Conditions
Prostate Cancer
Interventions
Docetaxel, Imatinib Mesylate, Leuprolide, Goserelin Acetate
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Male only
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 28, 2015 · Synced Oct 24, 2026, 4:24 AM EDT
Terminated Phase 2 Interventional Results available

Ipilimumab + Androgen Depravation Therapy in Prostate Cancer

NCT01377389
View directory record Official record
Conditions
Prostate Cancer
Interventions
Ipilimumab, Leuprolide, Goserelin, Degarelix
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 29, 2023 · Synced Oct 24, 2026, 4:24 AM EDT
Recruiting Phase 2 Interventional

Effects of Relugolix vs Leuprolide on Cardiac Function in Patients With Prostate Cancer

NCT06330805
View directory record Official record
Conditions
Prostate Adenocarcinoma, Stage IIB Prostate Cancer AJCC v8, Stage IIC Prostate Cancer AJCC v8
Interventions
Biospecimen Collection, Contrast Agent, Leuprolide, Magnetic Resonance Imaging, Physical Performance Testing, Relugolix
Procedure · Other · Drug
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Oct 24, 2026, 4:24 AM EDT
Completed Phase 4 Interventional

A Six-Month, Open-Label, Crossover Study Of the Maintenance Of Serum Testosterone And PSA Suppression After Switching Between Lupron 22.5 Mg And Eligard 22.5 Mg Or Zoladex 10.8 Mg And Eligard 22.5 Mg In Patients With Advanced Prostate Cancer

NCT00220194
View directory record Official record
Conditions
Cancer of Prostate
Interventions
leuprolide acetate
Drug
Lead sponsor
San Bernardino Urological Associates Medical Group Inc
Other
Eligibility
18 Years and older · Male only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
San Bernardino, California
Source: ClinicalTrials.gov public record
Updated Oct 14, 2016 · Synced Oct 24, 2026, 4:24 AM EDT
Completed Phase 2 Interventional Results available

Extended Endocrine Therapy for Premenopausal Women With Breast Cancer

NCT00903162
View directory record Official record
Conditions
Breast Cancer
Interventions
leuprolide, letrozole, zoledronic acid
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
4
States / cities
Denver, Colorado • Boston, Massachusetts • Newton, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 18, 2016 · Synced Oct 24, 2026, 4:24 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer

NCT01415960
View directory record Official record
Conditions
Prostate Cancer
Interventions
Leuprolide acetate 22.5 mg depot, GP-Pharm SA
Drug
Lead sponsor
GP-Pharm
Industry
Eligibility
18 Years and older · Male only
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
25
States / cities
San Diego, California • Daytona Beach, Florida • Ocala, Florida + 22 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2017 · Synced Oct 24, 2026, 4:24 AM EDT
Completed Not applicable Interventional

Initiation of Androgen Deprivation Therapy for Prostate Cancer Using Degarelix Followed by Leuprolide

NCT01344564
View directory record Official record
Conditions
Prostate Cancer
Interventions
Degarelix acetate, Leuprolide acetate
Drug
Lead sponsor
Urology of Virginia
Other
Eligibility
18 Years and older · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Virginia Beach, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 18, 2013 · Synced Oct 24, 2026, 4:24 AM EDT
Terminated Phase 3 Interventional Results available

External Beam Radiation Therapy (EBRT) With or Without Hormonal Therapy in Prostate Cancer

NCT00388804
View directory record Official record
Conditions
Prostate Cancer
Interventions
Radiation Therapy, Bicalutamide, Leuprolide, Goserelin, Flutamide, Questionnaire
Procedure · Drug · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Male only
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 8, 2012 · Synced Oct 24, 2026, 4:24 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Impact of Hot Flashes on Sleep and Mood Disturbance

NCT01116401
View directory record Official record
Conditions
Menopause, Depression, Hot Flashes
Interventions
leuprolide
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 24, 2026, 4:24 AM EDT
Completed Phase 1 Interventional Results available

A Treatment Study for Premenstrual Syndrome (PMS)

NCT00001259
View directory record Official record
Conditions
Premenstrual Syndrome, Menstruation Disturbances
Interventions
Leuprolide, Estradiol Patches, Progesterone, Placebo patch, Placebo injection, Placebo suppository
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 45 Years · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1992 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 2, 2023 · Synced Oct 24, 2026, 4:24 AM EDT
Completed Phase 3 Interventional Results available

Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate in Subjects With Advanced Prostate Carcinoma

NCT02234115
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Leuprolide Mesylate
Drug
Lead sponsor
Foresee Pharmaceuticals Co., Ltd.
Industry
Eligibility
18 Years and older · Male only
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
8
States / cities
Homewood, Alabama • Laguna Hills, California • San Diego, California + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2019 · Synced Oct 24, 2026, 4:24 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Characterizing the Neural Substrates of Irritability in Women: an Experimental Neuroendocrine Model

NCT04051320
View directory record Official record
Conditions
Perinatal Depression, Post Partum Depression, Depression, Postpartum, Depression
Interventions
Leuprolide Acetate 3.75 MG/ML, Estradiol 2 Mg tablet, Micronized progesterone
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
22 Years to 45 Years · Female only
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 25, 2023 · Synced Oct 24, 2026, 4:24 AM EDT